Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 2019-2022

  Wu, Xue Yan ^a   Huang, Xin En ^a   You, Shan Xi ^b   Lu, Yan Yan ^a   Cao, Jie ^a   Liu, Jin ^a   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b The No4 Hospital of Taizhou of Jiangsu Province   (China)

Author keywords

Chemotherapy; Colorectal carcinoma; Pemetrexed; Phase II trial

Indexed keywords

EID: 84880351832     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.2019     Document Type: Article

References (30)

1. Atkins JN, Jacobs SA, Wieand HS, et al (2005). Pemetrexed/ oxaliplatin for first-line treatment of patients with advanced colorectal cancer, a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer, 5, 181-7.
2. Conti JA, Kemeny N, Saltz L et al (1996). Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol, 14, 709-15.
3. Cripps C Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer, an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9.
4. Cunningham D, Pyrhonen S, James RD, et al (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352, 1413-8.
5. De Gramont A, Figer A, Seymour M, et al (1998). Randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol, 17, 257a (Abstr).
6. Findlay M,Van Cutsem E, KochaW, et al (1997). A randomized phase II study of capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol, 16, 227a (Abstr).
7. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China, final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
8. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.
9. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
10. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
11. John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma, results from a phase II study. Cancer, 88, 1807813.
12. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.
13. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
14. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
15. Li Y, Yan PW, Huang XE, Li CG (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
16. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.
17. Nogue M, Segui MA, Batiste E et al (1996). Phase II study of oral Tegafur (TF) and low-dose oral leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol, 15, 200 (Abstr).
18. Shih C, Gosset L, Gates S, et al (1996). LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase(DHFR) and thymidylate synthase (TS), Multiple folate enzyme inhibition. Ann Oncol, 7, 85.
19. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
20. Sudoh J, Gemma A (2008). [Pemetrexed]. Gan To Kagaku Ryoho, 35, 1033-8.
21. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
22. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
23. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
24. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
25. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
26. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
27. Yu DS, Huang XE, Zhou JN (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
28. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility, a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
29. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
30. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer, a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.